Teachers Retirement System of The State of Kentucky maintained its position in Repligen Corporation (NASDAQ:RGEN) during the first quarter, according to its most recent disclosure with the SEC. The firm owned 11,500 shares of the biotechnology company’s stock at the end of the first quarter. Teachers Retirement System of The State of Kentucky’s holdings in Repligen Corporation were worth $405,000 as of its most recent filing with the SEC.
Several other institutional investors have also bought and sold shares of RGEN. State of Alaska Department of Revenue boosted its stake in shares of Repligen Corporation by 2.2% in the first quarter. State of Alaska Department of Revenue now owns 3,740 shares of the biotechnology company’s stock worth $131,000 after buying an additional 80 shares during the last quarter. NBW Capital LLC boosted its stake in shares of Repligen Corporation by 0.5% in the first quarter. NBW Capital LLC now owns 22,655 shares of the biotechnology company’s stock worth $797,000 after buying an additional 118 shares during the last quarter. Louisiana State Employees Retirement System boosted its stake in shares of Repligen Corporation by 1.5% in the first quarter. Louisiana State Employees Retirement System now owns 13,800 shares of the biotechnology company’s stock worth $486,000 after buying an additional 200 shares during the last quarter. Arizona State Retirement System boosted its stake in shares of Repligen Corporation by 1.1% in the first quarter. Arizona State Retirement System now owns 17,626 shares of the biotechnology company’s stock worth $620,000 after buying an additional 200 shares during the last quarter. Finally, Mason Street Advisors LLC boosted its stake in shares of Repligen Corporation by 7.0% in the first quarter. Mason Street Advisors LLC now owns 7,914 shares of the biotechnology company’s stock worth $279,000 after buying an additional 521 shares during the last quarter. Institutional investors own 99.49% of the company’s stock.
Shares of Repligen Corporation (NASDAQ RGEN) traded down 1.27% on Tuesday, hitting $41.08. 108,050 shares of the company’s stock were exchanged. The stock’s 50 day moving average is $41.83 and its 200 day moving average is $36.83. The firm has a market cap of $1.53 billion, a P/E ratio of 80.39 and a beta of 1.30. Repligen Corporation has a 12 month low of $26.16 and a 12 month high of $46.81.
Repligen Corporation (NASDAQ:RGEN) last released its quarterly earnings data on Thursday, August 3rd. The biotechnology company reported $0.20 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.15 by $0.05. The firm had revenue of $32.40 million for the quarter, compared to analysts’ expectations of $31.72 million. Repligen Corporation had a net margin of 15.61% and a return on equity of 9.90%. The company’s revenue for the quarter was up 11.0% compared to the same quarter last year. During the same quarter last year, the business posted $0.16 earnings per share. On average, equities analysts predict that Repligen Corporation will post $0.59 earnings per share for the current year.
A number of equities research analysts have recently issued reports on RGEN shares. Janney Montgomery Scott upped their target price on shares of Repligen Corporation from $42.00 to $47.00 in a report on Friday, June 23rd. TheStreet raised shares of Repligen Corporation from a “c+” rating to a “b-” rating in a report on Friday. BidaskClub raised shares of Repligen Corporation from a “hold” rating to a “buy” rating in a report on Wednesday, August 9th. Zacks Investment Research raised shares of Repligen Corporation from a “hold” rating to a “buy” rating and set a $42.00 price target on the stock in a report on Wednesday, June 14th. Finally, First Analysis reissued an “equal weight” rating and issued a $40.00 price target on shares of Repligen Corporation in a report on Friday, April 21st. Two investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The stock currently has an average rating of “Buy” and an average price target of $42.00.
Repligen Corporation Company Profile
Repligen Corporation is a bioprocessing company. The Company is focused on the development, manufacture and commercialization of products used to improve the interconnected phases of the biological drug manufacturing process. The Company’s portfolio includes protein products, chromatography products, and filtration products.
Receive News & Ratings for Repligen Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen Corporation and related companies with MarketBeat.com's FREE daily email newsletter.
